ATE495747T1 - Kristalline form des ibandronat-natriums und herstellungsverfahren dafür - Google Patents

Kristalline form des ibandronat-natriums und herstellungsverfahren dafür

Info

Publication number
ATE495747T1
ATE495747T1 AT05791142T AT05791142T ATE495747T1 AT E495747 T1 ATE495747 T1 AT E495747T1 AT 05791142 T AT05791142 T AT 05791142T AT 05791142 T AT05791142 T AT 05791142T AT E495747 T1 ATE495747 T1 AT E495747T1
Authority
AT
Austria
Prior art keywords
ibandronate sodium
crystalline form
production process
ray
sodium
Prior art date
Application number
AT05791142T
Other languages
English (en)
Inventor
Revital Lifshitz-Liron
Thomas Bayer
Judith Aronhime
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35968334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE495747(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE495747T1 publication Critical patent/ATE495747T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Artificial Filaments (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Secondary Cells (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Liquid Crystal Substances (AREA)
AT05791142T 2004-08-23 2005-08-23 Kristalline form des ibandronat-natriums und herstellungsverfahren dafür ATE495747T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60402604P 2004-08-23 2004-08-23
US69086705P 2005-06-16 2005-06-16
PCT/US2005/030500 WO2006024024A2 (en) 2004-08-23 2005-08-23 Solid and crystalline ibandronate sodium and processes for preparation thereof

Publications (1)

Publication Number Publication Date
ATE495747T1 true ATE495747T1 (de) 2011-02-15

Family

ID=35968334

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08002626T ATE520406T1 (de) 2004-08-23 2005-08-23 Kristalline form des ibandronat-natriums
AT05791142T ATE495747T1 (de) 2004-08-23 2005-08-23 Kristalline form des ibandronat-natriums und herstellungsverfahren dafür

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT08002626T ATE520406T1 (de) 2004-08-23 2005-08-23 Kristalline form des ibandronat-natriums

Country Status (12)

Country Link
US (1) US7563918B2 (de)
EP (2) EP1930011B1 (de)
JP (1) JP4559431B2 (de)
KR (2) KR20090120011A (de)
CN (1) CN101022812A (de)
AT (2) ATE520406T1 (de)
CA (1) CA2576659A1 (de)
DE (2) DE602005025977D1 (de)
ES (1) ES2358269T3 (de)
IL (1) IL181298A (de)
PT (2) PT1930011E (de)
WO (1) WO2006024024A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2401769T5 (es) 2003-09-12 2020-07-01 Amgen Inc Formulación de disolución rápida de cinacalcet HCl
JP5828607B2 (ja) 2005-02-01 2015-12-09 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ イバンドロネート多形ｂ
KR100908529B1 (ko) * 2005-02-01 2009-07-20 에프. 호프만-라 로슈 아게 이반드로네이트 다형체 에이
WO2007074475A2 (en) * 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate
WO2008014510A2 (en) * 2006-07-28 2008-01-31 Dr. Reddy's Laboratories Limited Crystalline form a of ibandronic acid and process for the preparation
US20090012047A1 (en) * 2006-11-16 2009-01-08 Eran Turgeman Crystalline forms of ibandronate sodium
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
CN101679465B (zh) 2007-04-11 2013-08-21 霍夫曼-拉罗奇有限公司 伊班膦酸盐的制备方法
KR20100014728A (ko) * 2007-04-19 2010-02-10 닥터 레디스 레보러터리즈 리미티드 이반드로네이트 나트륨 다형태
US20090042839A1 (en) * 2007-08-09 2009-02-12 Sharon Avhar-Maydan Crystalline forms of ibandronate sodium
WO2009053445A2 (en) * 2007-10-26 2009-04-30 Chemo Ibérica, S.A. Polymorphic forms of ibandronate sodium and processes for preparation thereof
EP2128166A1 (de) 2008-05-20 2009-12-02 Chemo Ibérica, S.A. Polymorphe Ibandronat-Natrium-Formen und Verfahren zu ihrer Herstellung
US20090118239A1 (en) * 2007-11-05 2009-05-07 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of ibandronate disodium
EP2180003A1 (de) 2008-10-21 2010-04-28 Zentiva, k.s. Herstellung von Trinatriumbandronat
PL2395983T3 (pl) 2009-02-13 2020-09-07 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania
WO2010131267A1 (en) 2009-05-15 2010-11-18 Nox Medical System and methods using flexible capacitive electrodes for measuring biosignals
WO2011016738A1 (en) 2009-08-05 2011-02-10 Zaklady Farmaceutyczne Polpharma Sa A process for the synthesis of 1-hydroxy-3-(n-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate
UA105556C2 (uk) 2010-01-27 2014-05-26 Віів Гелскер Компані Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
EP2584962B1 (de) 2010-06-25 2014-09-10 Nox Medical ehf. Biometrischer bandverbinder
SMT201700124T1 (it) 2010-09-03 2017-05-08 Valneva Austria Gmbh Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
WO2013179305A1 (en) * 2012-06-01 2013-12-05 Hetero Research Foundation Ibandronate sodium solid dispersion
WO2014170909A2 (en) 2013-04-01 2014-10-23 Hetero Research Foundation Process for pomalidomide
EP3065638B1 (de) 2013-11-06 2024-01-10 Nox Medical ehf. Verfahren, vorrichtung und system zur messung einer atemanstrengung
EP3578546A1 (de) 2013-11-15 2019-12-11 Akebia Therapeutics Inc. Feste formen von {[5-(3-chlorophenyl)-3-hydroxypyridin-2-carbonyl]amino}essigsäure, zusammensetzungen und verwendungen davon
WO2018033889A1 (en) 2016-08-19 2018-02-22 Nox Medical Method, apparatus, and system for measuring respiratory effort of a subject
WO2018220606A1 (en) 2017-06-02 2018-12-06 Nox Medical Ehf Coherence-based method, apparatus, and system for identifying corresponding signals of a physiological study
EP3678543A1 (de) 2017-09-08 2020-07-15 Nox Medical System und verfahren zur nichtinvasiven bestimmung einer internen komponente der respiratorischen belastung

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
JP2639721B2 (ja) 1988-12-27 1997-08-13 富士重工業株式会社 内燃機関の燃焼室
US5652227A (en) * 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
DE19637890A1 (de) * 1996-09-17 1998-03-19 Max Planck Gesellschaft Biphosphonat-Liposomen
DE19828450A1 (de) * 1998-06-26 1999-12-30 Hassan Jomaa Bisphosphonsäuren und deren Derivate enthaltende Arzneimittel zur Prophylaxe und zur Behandlung von Autoimmunkrankheiten sowie von Allergien
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
EP0998933A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
DK1178810T3 (da) * 1999-05-21 2005-07-11 Novartis Ag Anvendelse af bisphosphonsyrer til behandling af angiogenese
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
JP3923800B2 (ja) * 2000-05-05 2007-06-06 エフ．ホフマン−ラ ロシュ アーゲー ビスホスホン酸またはそれらの塩を含む、皮下投与のためのゲル様医薬組成物
US8052987B2 (en) * 2000-06-20 2011-11-08 Novartis Pharmaceuticals Corporation Method of administering bisphosphonates
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
EP1228761A3 (de) * 2001-02-01 2003-01-15 Riderway Corporation Flüssige pharmazeutische Zusammensetzung zur Behandlung von Knochenerkrankungen
ITMI20020908A1 (it) 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione di sodio alendronato
KR20140021045A (ko) * 2002-05-10 2014-02-19 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
TW200638946A (en) * 2002-05-17 2006-11-16 Wyeth Corp Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
NZ536273A (en) * 2002-12-20 2007-08-31 Hoffmann La Roche High dose ibandronate formulation
EP2206717B1 (de) * 2003-12-23 2013-03-27 Alchymars S.p.A. Prozess zur Herstellung von Alkyl- und Aryl diphosphonsäuren und deren Salzen
WO2006002348A2 (en) * 2004-06-23 2006-01-05 Teva Pharmaceutical Industies Ltd. Solid and crystalline ibandronic acid
JP5828607B2 (ja) 2005-02-01 2015-12-09 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ イバンドロネート多形ｂ
KR100908529B1 (ko) 2005-02-01 2009-07-20 에프. 호프만-라 로슈 아게 이반드로네이트 다형체 에이
WO2007074475A2 (en) 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate

Also Published As

Publication number Publication date
WO2006024024A2 (en) 2006-03-02
CA2576659A1 (en) 2006-03-02
DE602005025977D1 (de) 2011-03-03
JP4559431B2 (ja) 2010-10-06
EP1713489B1 (de) 2011-01-19
IL181298A0 (en) 2007-07-04
DE202005021414U1 (de) 2008-03-20
KR20090120011A (ko) 2009-11-23
PT1930011E (pt) 2011-09-16
EP1930011B1 (de) 2011-08-17
CN101022812A (zh) 2007-08-22
EP1930011A2 (de) 2008-06-11
JP2007512237A (ja) 2007-05-17
WO2006024024A3 (en) 2006-06-29
IL181298A (en) 2011-04-28
KR20070043043A (ko) 2007-04-24
EP1713489A2 (de) 2006-10-25
ES2358269T3 (es) 2011-05-09
PT1713489E (pt) 2011-03-03
ATE520406T1 (de) 2011-09-15
US7563918B2 (en) 2009-07-21
EP1930011A3 (de) 2008-06-18
US20070179119A1 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
DE602005025977D1 (de) Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
TW200716121A (en) Acetylenyl-pyrazolo-pyrimidine derivatives as mGluR2 antagonists
MX2008013782A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen.
TW200716558A (en) Heteroaroyl-substituted serineamides
NO20063517L (no) Ny krystallinsk form v av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
ECSP066914A (es) FORMA CRISTALINA dd DEL CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
MY141306A (en) New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it
TW200738241A (en) Pyridazine derivatives
MY139399A (en) Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
NO20064596L (no) Delta-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
TW200806300A (en) New therapeutic combinations for the treatment of depression
MY142856A (en) New crystalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it
TW200628154A (en) Organic compounds
ATE519373T1 (de) Teezusammensetzung und herstellungsverfahren dafür
MX2009010505A (es) Derivados de piridina y pirimidina como antagonistas de mglur2.
MX2007013084A (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion.
MY143557A (en) Beta-crystalline form of perindopril arginine salt, process for its preparation, and pharmaceutical compositions containing it
GEP20125433B (en) α CRYSTALLINE FORM OF THE ARGININE SALT OF PERINDOPRIL, PROCESS FOR PREPARING IT, AND PHARMACEUTICAL COMPOSITIONS COMPRISING IT
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
TW200740764A (en) Pyrazolone derivatives
CY1111836T1 (el) Ενωσεις aminoalkoxy aryl sulfonamide και η χρηση τους σαν συνδετων (ligands) 5-ητ6
TW200800993A (en) Organic compounds
UA94080C2 (ru) Ациклически-замещенные производные фуропиримидина и их применение для лечения сердечно-сосудистых заболеваний
EA200900936A1 (ru) Аморфные и кристаллические формы ривастигмина гидротартрата
TW200833696A (en) Spiro-piperidine derivatives

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties